Picture of the author
Catch Cancer Early, When it Counts the Most
HelioLiver™ is a revolutionary new blood test that offers at-risk patients an easy way to detect early liver cancer
Exclusively offered in partnership with
<50%Cancers identified at an early stage
Early liver cancer detection
isn't early enough
Less than half of all liver cancers in the US are diagnosed at an early stage when the disease is still localized. Early detection of liver cancer significantly improves outcomes for patients, allowing for a higher survival rate, and more time to treat the disease. Detecting cancer early opens up the door for potentially curative treatment options, such as surgery and transplant.
A Simple Blood Test for Liver Cancer
Picture of the author
Introducing the HelioLiver™ Test
HelioLiver reimagines how we find and fight liver cancer by simplifying screening for you and your patients. Now, you can efficiently screen more patients with one simple, affordable blood test that integrates seamlessly with in-office patient care.
Learn about our test
WHO THIS TEST IS FOR

Almost 90% of liver cancer is made up of hepatocellular carcinoma (HCC).

Patients at risk for HCC include those with: pre-existing cirrhosis, chronic hepatitis B or hepatitis C, excessive alcohol use, and nonalcoholic fatty liver disease (NAFLD). Less-prevalent conditions, such as hereditary hemochromatosis, primary biliary cholangitis (PBC), and Wilson's disease, have also been associated with HCC development.

Elevating the Standard of Care
Compared to traditional early liver cancer detection methods, HelioLiver has shown improvements across the board.
Easy to Use
A simple blood draw can be done during patient routine visits or readily available options
High Sensitivity
Our test is more sensitive than currently available blood based tests for the early detection of HCC
Proven reliability
Get simple, easy-to-interpret results that are immediately actionable for providers and patients
Improved Patient Adherence
Remove barriers to routine screening with expanded availability and convenience
Harness Cutting-Edge Technology for HCC Surveillance

By combining the results of cell-free DNA methylation testing with data from protein tumor markers and other clinical information, the HelioLiver test delivers superior performance characteristics when compared to traditional blood tests for hepatocellular carcinoma (HCC)

Our Clinical Evidence
HELIOLIVER
91% Specificity		AFPGALAD
Early Stage Sensitivity76%57%65%
Overall Sensitivity85%62%75%
Picture of the author

Offered exclusively via our partner

Fulgent Genetics

HelioHealth has partnered with the NGS pioneers at Fulgent Genetics to revolutionize cancer diagnostic technology and provide the highest standards of care with CLIA and CAP-certified laboratories.

Start today with HelioLiver™
Our team is happy to hear from you and answer any questions you may have